# Development of Cancer Immunoprevention in a High-Risk Population of Canadian Inuits: Characterization of Frame-Shift Neoantigen Expression in Homozygous Individuals and Carriers of PMS2 Mutations

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $24,717

## Abstract

Project hypothesizes that the recurrent frame-shift mutations observed in Lynch Syndrome will also occur in CMMRD Syndrome and that the neoantigen vaccine strategy and reagents will be directly relevant to cancer prevention in CMMRD Syndrome.

## Key facts

- **NIH application ID:** 10725425
- **Project number:** 75N91019D00024-P00018-759102000003-56
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LEONARD FREEDMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $24,717
- **Award type:** —
- **Project period:** 2020-08-31 → 2022-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10725425

## Citation

> US National Institutes of Health, RePORTER application 10725425, Development of Cancer Immunoprevention in a High-Risk Population of Canadian Inuits: Characterization of Frame-Shift Neoantigen Expression in Homozygous Individuals and Carriers of PMS2 Mutations (75N91019D00024-P00018-759102000003-56). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10725425. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*